Insider Selling: Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) CEO Sells $404,000.00 in Stock

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRXGet Free Report) CEO Christopher Gibson sold 40,000 shares of the business’s stock in a transaction that occurred on Thursday, March 28th. The stock was sold at an average price of $10.10, for a total value of $404,000.00. Following the transaction, the chief executive officer now directly owns 1,043,524 shares in the company, valued at approximately $10,539,592.40. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Christopher Gibson also recently made the following trade(s):

  • On Wednesday, March 6th, Christopher Gibson sold 36,319 shares of Recursion Pharmaceuticals stock. The stock was sold at an average price of $11.86, for a total value of $430,743.34.
  • On Wednesday, February 7th, Christopher Gibson sold 48,272 shares of Recursion Pharmaceuticals stock. The stock was sold at an average price of $9.22, for a total value of $445,067.84.
  • On Wednesday, January 3rd, Christopher Gibson sold 30,853 shares of Recursion Pharmaceuticals stock. The stock was sold at an average price of $9.49, for a total value of $292,794.97.

Recursion Pharmaceuticals Trading Down 6.4 %

Shares of RXRX stock opened at $8.77 on Wednesday. The stock has a market cap of $2.06 billion, a P/E ratio of -5.66 and a beta of 0.76. The stock has a 50 day simple moving average of $11.11 and a 200 day simple moving average of $9.07. Recursion Pharmaceuticals, Inc. has a 1 year low of $4.54 and a 1 year high of $16.75.

Recursion Pharmaceuticals (NASDAQ:RXRXGet Free Report) last issued its quarterly earnings results on Tuesday, February 27th. The company reported ($0.40) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.46) by $0.06. The business had revenue of $10.89 million during the quarter, compared to analysts’ expectations of $12.37 million. Recursion Pharmaceuticals had a negative return on equity of 72.88% and a negative net margin of 735.99%. Analysts forecast that Recursion Pharmaceuticals, Inc. will post -1.63 EPS for the current year.

Institutional Investors Weigh In On Recursion Pharmaceuticals

Institutional investors have recently made changes to their positions in the stock. Profund Advisors LLC boosted its stake in shares of Recursion Pharmaceuticals by 209.0% in the third quarter. Profund Advisors LLC now owns 184,235 shares of the company’s stock valued at $1,409,000 after buying an additional 124,621 shares during the period. Citigroup Inc. raised its position in Recursion Pharmaceuticals by 165.3% during the third quarter. Citigroup Inc. now owns 470,512 shares of the company’s stock valued at $3,599,000 after purchasing an additional 293,174 shares in the last quarter. Pathstone Family Office LLC acquired a new position in Recursion Pharmaceuticals during the third quarter valued at approximately $93,000. UBS Group AG raised its position in Recursion Pharmaceuticals by 103.1% during the third quarter. UBS Group AG now owns 342,679 shares of the company’s stock valued at $2,621,000 after purchasing an additional 173,954 shares in the last quarter. Finally, Principal Financial Group Inc. raised its position in Recursion Pharmaceuticals by 1,479.8% during the third quarter. Principal Financial Group Inc. now owns 645,475 shares of the company’s stock valued at $4,938,000 after purchasing an additional 604,618 shares in the last quarter. 89.06% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

A number of brokerages have recently issued reports on RXRX. TD Cowen began coverage on Recursion Pharmaceuticals in a report on Friday, January 26th. They set a “market perform” rating for the company. Needham & Company LLC boosted their price objective on Recursion Pharmaceuticals from $15.00 to $17.00 and gave the stock a “buy” rating in a report on Wednesday, February 28th. Finally, KeyCorp boosted their price objective on Recursion Pharmaceuticals from $15.00 to $16.00 and gave the stock an “overweight” rating in a report on Monday, March 4th. Three equities research analysts have rated the stock with a hold rating and two have assigned a buy rating to the company. According to MarketBeat.com, the stock currently has an average rating of “Hold” and an average price target of $12.75.

View Our Latest Stock Report on RXRX

Recursion Pharmaceuticals Company Profile

(Get Free Report)

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.

Further Reading

Insider Buying and Selling by Quarter for Recursion Pharmaceuticals (NASDAQ:RXRX)

Receive News & Ratings for Recursion Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Recursion Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.